Background:  Human papillomaviruses, particularly type 16 (designated HPV16), infect the genital tract and may lead to cervical cancer. Protection against HPV16 is thought to be provided by neutralizing antibodies directed to the major caspid protein L1 of HPV16. HPV16 L1 forms the pentameric assembly unit of the viral shell, and the binding of HPV16 L1 to the cell surface without the involvement of minor capsid protein L2 is believed to be the first step of HPV16 infection. The L1-binding domain located near the C-terminus of L2 binds L1 prior to completion of capsid assembly and is required for efficient encapsidation of the viral genome. In addition, the C-terminus of L1 is necessary for both DNA binding and DNA packaging. Expression of the late gene L1 is restricted to the upper layers of the infected epithelium. HPV16 L1 is able to package unrelated plasmid DNA in vitro and deliver the foreign DNA to eukaryotic cells with the subsequent expression of the encoded gene. L1 shows a diffuse nuclear distribution whereas L2 is localized to punctate nuclear regions identified as promonocytic leukemia protein oncogenic domains (PODs). Coexpression of L1 and L2 induces a relocalization of L1 into the PODs.

Description: Rabbit polyclonal to HPV16 L2

Immunogen: KLH conjugated synthetic peptide derived from HPV16 L2

Specificity:  ·Reacts with Human.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 52 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/100-500;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.